Kythera Biopharmaceuticals has moved closer to launching an initial public offering of 4 million shares that it expects will price at $14 to $16 a share, according to a filing Monday with the Securities and Exchange Commission.

The Calabasas company, which is developing a prescription treatment to reduce chin fat, would raise about $60 million at the mid-point of the range. Shares would be listed on the Nasdaq Global Market under the ticker symbol “KYTH.”

The company would have an estimated market value of $275 million on a fully diluted basis if shares are priced at $15, according to institutional research and services firm Rennaisance Capital of Greenwich, Conn. Kythera has a number of venture backers including Versant Ventures, Arch Ventures and Jafco.

Founded in 2005, Kythera has a drug in late-stage clinical studies that would be the first injectable treatment to reduce chin fat. It retained rights to develop and commercialize the drug, known as ATX-101, in the United States and Canada. It licensed the rights in the rest of the world to German pharmaceutical giant Bayer AG. Kythera completed enrollment of patients for two U.S. studies and one Canadian study earlier this month.

The company plans to use IPO proceeds to finance the studies, conduct research and development on other products and for general corporate purposes. It reported a net loss of $11.1 million last year on $12.9 million in Bayer license income. In September, the company raised $37.4 million in a Series D funding round, which brought the total raised to date to $108 million.

J.P. Morgan and Goldman Sachs are the joint bookrunners on the IPO.